[HTML][HTML] Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments
S Richter, C Steenblock, A Fischer, S Lemm… - Theranostics, 2024 - ncbi.nlm.nih.gov
Radionuclide therapies are an important tool for the management of patients with
neuroendocrine neoplasms (NENs). Especially [131 I] MIBG and [177 Lu] Lu-DOTA-TATE …
neuroendocrine neoplasms (NENs). Especially [131 I] MIBG and [177 Lu] Lu-DOTA-TATE …
The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options …
A Bracigliano, AL Marretta, LP Guerrera, R Simioli… - Pharmaceuticals, 2024 - mdpi.com
Pheochromocytomas (PCCs) and Paragangliomas (PGLs), commonly known as PPGLs to
include both entities, are rare neuroendocrine tumors that may arise in the context of …
include both entities, are rare neuroendocrine tumors that may arise in the context of …
Succinate dehydrogenase mutations in head and neck paragangliomas: A systematic review and meta‐analysis of individual patients' data
Background Head and neck paragangliomas (HNPs) have been associated with gene
mutations in the succinate dehydrogenase (SDH) complex, but the clinical significance …
mutations in the succinate dehydrogenase (SDH) complex, but the clinical significance …
Advances in Radioligand Theranostics in Oncology
IO Lawal, SO Abubakar, H Ndlovu… - Molecular Diagnosis & …, 2024 - Springer
Theranostics with radioligands (radiotheranostics) has played a pivotal role in oncology.
Radiotheranostics explores the molecular targets expressed on tumor cells to target them for …
Radiotheranostics explores the molecular targets expressed on tumor cells to target them for …
Peptide receptor radionuclide therapy with 177Lu-or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single …
M Rubino, GD Di Stasio, L Bodei, S Papi, PA Rocca… - Endocrine, 2024 - Springer
Abstract Background Malignant pheochromocytomas (PCCs) and paragangliomas (PGLs)
are rare tumors and available systemic therapies are limited. Aim To explore the role of …
are rare tumors and available systemic therapies are limited. Aim To explore the role of …
Imaging of pheochromocytomas and paragangliomas
HJLM Timmers, D Taïeb, K Pacak… - Endocrine …, 2024 - academic.oup.com
Pheochromocytomas/paragangliomas are unique in their highly variable molecular
landscape driven by genetic alterations, either germline or somatic. These mutations …
landscape driven by genetic alterations, either germline or somatic. These mutations …